Intensive blood pressure lowering in patients with and patients without type 2 diabetes: A pooled analysis from two randomized trials

Diabetes Care

Volumn 41, Issue 6, 2018, Pages 1142-1148

  Brouwer, Tom F ^a   Vehmeijer, Jim T ^a   Kalkman, Deborah N ^a   Berger, Wouter R ^a,b   Van Den Born, Bert Jan H ^a   Peters, Ron J ^a   Knops, Reinoud E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; FACTORIAL DESIGN; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; BLOOD PRESSURE; COMPLICATION; DRUG EFFECT; HEART FAILURE; META ANALYSIS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; SYSTOLE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; SYSTOLE; TREATMENT OUTCOME;

EID: 85046289958     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1722     Document Type: Article

References (22)

1. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989;13 (Suppl. 5):2-12
2. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes inmen andwomen:meta-analysis of 37prospective cohort studies. BMJ 2006;332:73-78
3. Kearney PM, WheltonM, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365:217-223
4. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
5. Wright JT Jr, Williamson JD, Whelton PK, et al.; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116
6. Rosendorff C, Lackland DT, Allison M, et al.; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement fromthe AmericanHeart Association, American College of Cardiology, and American Society of Hypertension. Hypertension 2015;65:1372-1407
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219
8. American Diabetes Association. Standards of medical care in diabetesd2013. Diabetes Care 2013;36(Suppl. 1):S11-S66
9. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311: 507-520
10. Ambrosius WT, Sink KM, Foy CG, et al.; SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014;11:532-546
11. Cushman WC, Grimm RH Jr, Cutler JA, et al.; ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(Suppl.): S44-S55
12. D'Agostino RB Sr, Vasan RS, PencinaMJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008;117:743-753
13. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2015
14. Perkovic V, Rodgers A. Redefining bloodpressure targets-SPRINT starts the marathon. N Engl J Med 2015;373:2175-2178
15. Malhotra R, Nguyen HA, Benavente O, et al. Association betweenmore intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: A systematic review and meta-analysis. JAMA Intern Med 2017;177:1498-1505
16. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus?. Overview and meta-analyses of randomized trials. J Hypertens 2017;35:922-944
17. Haller H, Ito S, Izzo JL Jr, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-917
18. Parving H-H, Brenner BM, McMurray JJV, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-2213
19. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559
20. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: Implications for entry and achieved blood pressure values compared with other trials. Hypertension 2016;67:808-812
21. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: Randomised parallel design controlled trial. BMJ 2011;342:d286
22. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: A position statement by the American Diabetes Association. Diabetes Care 2017;40:1273-1284